Assessment of Progesterone Receptors in Breast Carcinoma by PET with 21-18F-Fluoro-16α,17α-[(R)-(1′-α-furylmethylidene)Dioxy]-19-Norpregn-4-Ene-3,20-Dione

被引:67
作者
Dehdashti, Farrokh [1 ,2 ,3 ,4 ]
Laforest, Richard [1 ,2 ,3 ,4 ]
Gao, Feng [3 ,4 ,5 ]
Aft, Rebecca L. [3 ,4 ,6 ]
Dence, Carmen S. [1 ,2 ,4 ]
Zhou, Dong [1 ,2 ,4 ]
Shoghi, Kooresh I. [1 ,2 ,3 ,4 ]
Siegel, Barry A. [1 ,2 ,3 ,4 ]
Katzenellenbogen, John A. [7 ]
Welch, Michael J. [1 ,2 ,3 ,4 ]
机构
[1] Edward Mallinckrodt Inst Radiol, Div Nucl Med, St Louis, MO 63110 USA
[2] Edward Mallinckrodt Inst Radiol, Div Radiol Sci, St Louis, MO 63110 USA
[3] Alvin J Siteman Canc Ctr, St Louis, MO USA
[4] Washington Univ, Sch Med, St Louis, MO USA
[5] Univ Illinois, Div Biostat, Urbana, IL 61801 USA
[6] Univ Illinois, Dept Surg, Urbana, IL 61801 USA
[7] Univ Illinois, Dept Chem, Urbana, IL 61801 USA
基金
美国国家卫生研究院;
关键词
PET; progesterone receptor; breast cancer; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; METABOLIC FLARE; HER-2; STATUS; CANCER; TAMOXIFEN; AFFINITY; STRATEGIES; SURVIVAL; DISEASE;
D O I
10.2967/jnumed.111.098319
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This first-in-human study was designed to evaluate the safety and dosimetry of the progesterone analog 21-F-18-fluoro-16 alpha, 17 alpha-[(R)(1'-alpha-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione (F-18-FFNP), as well the feasibility of imaging tumor progesterone receptors (PRs) by PET in breast cancer. Methods: Women with breast cancer underwent PET with F-18-FFNP. Tumor F-18-FFNP uptake was assessed semiquantitatively by determining maximum standardized uptake value and tumor-to-normal breast (T/N) activity ratio and by Logan graphical analysis. The PET results were correlated with estrogen receptor (ER) and PR status, assessed by in vitro assays of the tumor tissue. The biodistribution of F-18-FFNP was measured in patients by whole-body PET, and human dosimetry was estimated. Results: Twenty patients with 22 primary breast cancers (16 PR-positive [PR+] and 6 PR-negative [PR-]) were evaluated. Tumor maximum standardized uptake value was not significantly different in PR+ and PR- cancers (mean +/- SD, 2.5 +/- 0.9 vs. 2.0 +/- 1.3, P = 0.386), but the T/N ratio was significantly greater in the PR+ cancers (2.6 +/- 0.9 vs. 1.5 +/- 0.3, P = 0.001). In addition, there was a significant correlation between distribution volume ratio and T/N ratio (r = 0.89; P = 0.001) but not between distribution volume ratio and either PR status or standardized uptake value, likely because of small sample size. On the basis of whole-body PET data in 12 patients, the gallbladder appeared to be the dose-limiting organ, with an average radiation dose of 0.113 mGy/MBq. The whole-body dose was 0.015 mGy/MBq, and the effective dose was 0.020 mSv/MBq. No adverse effects of F-18-FFNP were encountered. Conclusion: F-18-FFNP PET is a safe, noninvasive means for evaluating tumor PRs in vivo in patients with breast cancer. The relatively small absorbed doses to normal organs allow for the safe injection of up to 440 MBq of F-18-FFNP.
引用
收藏
页码:363 / 370
页数:8
相关论文
共 43 条
[11]   PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer [J].
Dehdashti, Farrokh ;
Mortimer, Joanne E. ;
Trinkaus, Kathryn ;
Naughton, Michael J. ;
Ellis, Matthew ;
Katzenellenbogen, John A. ;
Welch, Michael J. ;
Siegel, Barry A. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) :509-517
[12]   Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status [J].
Dowsett, M ;
Houghton, J ;
Iden, C ;
Salter, J ;
Farndon, J ;
A'Hern, R ;
Sainsbury, R ;
Baum, M .
ANNALS OF ONCOLOGY, 2006, 17 (05) :818-826
[13]  
Elledge RM, 2000, INT J CANCER, V89, P111, DOI 10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.3.CO
[14]  
2-N
[15]   Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer A Phase 2 Randomized Study [J].
Ellis, Matthew J. ;
Gao, Feng ;
Dehdashti, Farrokh ;
Jeffe, Donna B. ;
Marcom, P. Kelly ;
Carey, Lisa A. ;
Dickler, Maura N. ;
Silverman, Paula ;
Fleming, Gini F. ;
Kommareddy, Aruna ;
Jamalabadi-Majidi, S. ;
Crowder, Robert ;
Siegel, Barry A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (07) :774-780
[16]   Prognostic molecular markers in early breast cancer [J].
Esteva, FJ ;
Hortobagyi, GN .
BREAST CANCER RESEARCH, 2004, 6 (03) :109-118
[17]   Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites [J].
Gancberg, D ;
Di Leo, A ;
Cardoso, F ;
Rouas, G ;
Pedrocchi, M ;
Paesmans, M ;
Verhest, A ;
Bernard-Marty, C ;
Piccart, MJ ;
Larsimont, D .
ANNALS OF ONCOLOGY, 2002, 13 (07) :1036-1043
[18]   Endocrine therapy of breast cancer [J].
Goldhirsch, A ;
Colleoni, M ;
Gelber, RD .
ANNALS OF ONCOLOGY, 2002, 13 :61-68
[19]   Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma [J].
Gong, Y ;
Booser, DJ ;
Sneige, N .
CANCER, 2005, 103 (09) :1763-1769
[20]   Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma [J].
Grann, VR ;
Troxel, AB ;
Zojwalla, NJ ;
Jacobson, JS ;
Hershman, D ;
Neugut, AI .
CANCER, 2005, 103 (11) :2241-2251